Background: Prognostic factors among acute myeloid leukemia (AML) patients undergoing alloge-
| I N T R O D U C T I O N
Achieving minimal residual disease (MRD) negativity before allogeneic hematopoietic cell transplantation (allo-HCT) is associated with a reduced risk of relapse in acute myeloid leukemia (AML). 1, 2 Furthermore, MRD status at the time of HCT is arguably the most important prognostic determinant of relapse risk, dominating a number of other potential prognostic factors (e.g., cytogenetic risk group, graft source, conditioning intensity). 1, 3 However, still about 30% of patients who undergo allo-HCT in a MRD-negative state relapse, 1 arguing for the presence of additional prognostic factors among MRD-negative patients. Although such factors are largely unknown, they could be informative when patients are counseled on prognosis at the time of HCT.
We hypothesized that among MRD-negative patients, where MRD status is no longer a variable, specifics of previous treatments may reflect varying depths of remission and hence be prognostic. Using a retrospective review of our institutional experience with relative practice uniformity over more than a decade, we attempted to answer the following question: In AML patients in first complete remission (CR1) undergoing allo-HCT in a MRD-negative state, does a history of prior consolidation provide additional prognostic information?
| M E T H O D S
We retrospectively evaluated all consecutive patients with the following criteria: (i) Age > 18 years, (ii) AML in CR1 (with count recovery) MRD determination was similar to our previous study, 6 was consistent over the time period of study, and included antibodies for CD3, CD7, CD10, CD13, CD14, CD15, CD19, CD33, CD34, CD45, CD56, CD117, and HLA-DR. Briefly, we used a 4-color, 4-tube myeloid panel that collected at least 100,000 events per tube. We categorized cases as MRD-positive if they included an immunophenotypically atypical population of myeloblasts similar to those at the time of diagnosis (and/or different from normal myeloblasts) and comprising at least 0.5% of marrow cells. The theoretical limit of detection was approximately 0.1%.
The cumulative incidence method was used to estimate relapse while treating nonrelapse mortality (NRM) as a competing risk, and to estimate NRM while treating relapse as a competing risk. Kaplan-Meier curves were used to estimate overall survival (OS) and relapse-free survival (RFS). The log-rank test was used for comparative time-to-event analyses. Cox regression was used to determine the effect of prior consolidation on OS and RFS. Fine and Gray regression was used to determine the effect of prior consolidation on relapse and NRM. SAS 9.3 (SAS Institute, Inc., Cary, NC) and R 3.0.2 were used for analysis with 2-sided P values and a significance threshold of .05.
| R E S U L T S
From a total of 195 AML patients transplanted in CR1 and with available information about their induction and consolidation status, 126 Donor age is provided for non-UCB transplants. UCB grafts were matched at 4-6 of 6 HLA-A (antigen level), -B (antigen level) and -DRB1 (allele level) to the recipient, and in patients receiving two UCB units, similarly matched to each other. HLA match for UCB transplant is provided for the cord unit with the largest degree of disparity to the patient. Cytogenetic/Molecular risk was defined using European LeukemiaNet classification (2017 recommendations when molecular data available). 4, 7 Conditioning intensity was classified as MA or RI. More comprehensive multivariate analysis with a larger number of variables or interaction terms was prohibited by the sample size.
To address potential sources of bias, first we compared our included cohort of 126 patients with the remaining 69 patients who were not included. We made this comparison to make sure the included cohort was representative of all allografted AML patients in CR1. The only differences between these groups were in age, year of transplant, and conditioning intensity (data not shown). Specifically, the included cohort was transplanted more recently, was older, and had a higher frequency of reduced-intensity conditioning. These differences are explained by our emphasis in recent years on requesting for bone marrow biopsy slides and flow cytometry data from the time of diagnosis as obtained in the community in referral cases. Since available flow cytometry data from the time of diagnosis was an inclusion criterion, recently transplanted patients were more likely to be included. With the growing popularity of reduced-intensity conditioning permitting transplant in older ages, the included cohort was older and had a higher frequency of reduced-intensity conditioning. Next, we asked whether the decision on consolidation versus no consolidation was dependent upon postinduction MRD status. In a vast majority of patients, postinduction MRD status was not available to the treating physician and therefore it was likely not a factor in decision making. Although it cannot be determined with certainty, we believe donor availability was the major determinant of decision for consolidation versus no consolidation.
As patients in the consolidation group had a longer post-CR1 interval than the no-consolidation group at the time of HCT, a history of prior consolidation could have selected patients with less aggressive disease. First, the number of inductions and the diagnosis-to-CR interval were not different between the groups, arguing against major differences between the groups in terms of disease biology. Second, we considered patients with or without consolidation who were referred for HCT at a similar time interval from CR1 and assessed whether the apparent association of consolidation with outcome was only valid within a specific CR-to-HCT cohort. To this end, we stratified patients in groups with CR-to-HCT interval <2 versus 2 months (52 and 72 patients, respectively; unknown in 2 patients) and analyzed the association between consolidation (yes vs. no) and 5-year RFS in each stratum.
In this analysis, very similar patterns were observed in the two strata On the other hand, previous studies showing no impact of consolidation did not take MRD status into account and the heterogeneity in MRD status might have masked the effect of consolidation specifically in MRDnegative patients. 11, 12 Due to rapid availability of cord blood grafts for most patients and our preference not to delay HCT for consolidation in such cases, 13 our institutional experience is enriched in no-consolidation patients, allowing us to address the question of our study.
Several characteristics of our study population should be considered when interpreting our findings. should not yet be used for prospective decision-making. In MRD-negative patients at the end of induction, we decide about consolidation primarily based on donor availability, and for MRD-negative CR1 patients referred to us for HCT, we use consolidation history as a factor in prognostication.
A multi-center study has been designed to validate our results.
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